Alzheimer’s disease (AD) research is entering a decisive new era, one that is transforming both patient care and global biotech strategy. In 2025, the field is shifting beyond symptomatic treatments toward disease-modifying therapies that directly target the biological drivers of neurodegeneration. Fueled by breakthrough clinical data, regulatory momentum, and unprecedented investor confidence, this progress is … 2025 Alzheimer’s Drug Development: From Anti-Amyloid to Next-Gen Targets and a $15.5B Market Opportunity Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.